![Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Business Wire Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Business Wire](https://mms.businesswire.com/media/20191211005896/en/305625/5/puma_logo_JPEG.jpg)
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Business Wire
![Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting | Business Wire Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting | Business Wire](https://mms.businesswire.com/media/20170402005052/en/578722/5/Untitled-2.jpg)
Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting | Business Wire
![Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations – pharmaceutical daily Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations – pharmaceutical daily](http://www.pharmaceuticaldaily.com/wp-content/uploads/2017/05/Puma-Biotechnology.png)
Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations – pharmaceutical daily
![Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire](https://mms.businesswire.com/media/20191213005405/en/763006/5/4165450_121319_SABCS_2019_CONTROL_P5-14_Chan__poster_12-Dec-2019_FINAL.jpg?download=1)
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire
![Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Business Wire Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Business Wire](https://mms.businesswire.com/media/20191211005896/en/762417/22/Untitled-1.jpg)
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Business Wire
![Puma Biotechnology SUMMIT TrialUpdate on Regulatory Strategy PowerPoint Presentation, Free Online Download PPT PGLGTY Puma Biotechnology SUMMIT TrialUpdate on Regulatory Strategy PowerPoint Presentation, Free Online Download PPT PGLGTY](https://cdn.smackslide.com/cover/puma-biotechnology-summit-trialupdate-on-regulatory-strategy-pglgty.jpg)
Puma Biotechnology SUMMIT TrialUpdate on Regulatory Strategy PowerPoint Presentation, Free Online Download PPT PGLGTY
![Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire](https://mms.businesswire.com/media/20191213005405/en/763006/22/4165450_121319_SABCS_2019_CONTROL_P5-14_Chan__poster_12-Dec-2019_FINAL.jpg)
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire
![Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 AACR Annual Meeting | Business Wire Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 AACR Annual Meeting | Business Wire](https://mms.businesswire.com/media/20170404005596/en/579087/5/Puma_CONTROL_AACR_2017_poster_Figure_1_-_Final-%282%29-%281%29.jpg?download=1)
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 AACR Annual Meeting | Business Wire
![Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Business Wire Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Business Wire](https://mms.businesswire.com/media/20191211005896/en/762417/5/Untitled-1.jpg?download=1)
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Business Wire
![Female puma (Puma concolor) in shrubland of site 1 during high food... | Download Scientific Diagram Female puma (Puma concolor) in shrubland of site 1 during high food... | Download Scientific Diagram](https://www.researchgate.net/profile/Juan_Esparza-Carlos/publication/325404799/figure/fig2/AS:642893039538183@1530289053852/Female-puma-Puma-concolor-in-shrubland-of-site-1-during-high-food-trial-4-April_Q640.jpg)
Female puma (Puma concolor) in shrubland of site 1 during high food... | Download Scientific Diagram
![Puma Biotechnology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Neratinib HER2 Mutation Basket Study (SUMMIT Trial) Puma Biotechnology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Neratinib HER2 Mutation Basket Study (SUMMIT Trial)](https://storage.googleapis.com/afs-prod/media/media:e29c2598ca7a611ab528e449d00b4580/800.jpeg)